Critical Care Research Group, The Prince Charles Hospital and University of Queensland, Brisbane, Queensland, Australia.
Adult Intensive Care Services, The Prince Charles Hospital, Brisbane, Queensland, Australia.
BMJ Open. 2019 Jul 10;9(7):e029293. doi: 10.1136/bmjopen-2019-029293.
Extracorporeal membrane oxygenation (ECMO) provides cardiac and/or respiratory support when other therapies fail. Nosocomial infection is reported in up to 64% of patients receiving ECMO and increases morbidity and mortality. These patients are at high risk of infection due, in part, to the multiple invasive devices required in their management, the largest being the cannulae through which ECMO is delivered. Prevalence of nosocomial infection in ECMO patients, including ECMO cannula-related infection, is not well described across Australia and New Zealand.
This is a prospective, observational point prevalence study of 12 months duration conducted at 11 ECMO centres across Australia and New Zealand. Data will be collected for every patient receiving ECMO during 12 predetermined data collection weeks. The primary outcome is the prevalence of laboratory-confirmed bloodstream infection, and suspected or probable nosocomial infections; and the secondary outcomes include describing ECMO cannula dressing and securement practices, and adherence to local dressing and securement guidelines. Data collection will be finalised by March 2019.
Relevant ethical and governance approvals have been received. Study results will describe the prevalence of suspected and confirmed nosocomial infection in adult, paediatric and neonatal patients receiving ECMO across Australia and New Zealand. It is expected that the results will be hypothesis generating and lead to interventional trials aimed at reducing the high infection rates seen in this cohort. Results will be published in peer-reviewed journals and presented at relevant conferences.
ANZCTRN12618001109291; Pre-results.
体外膜肺氧合(ECMO)在其他治疗方法失败时提供心脏和/或呼吸支持。据报道,接受 ECMO 的患者中有高达 64%发生医院感染,这增加了发病率和死亡率。这些患者由于管理所需的多种侵入性设备(其中最大的是 ECMO 输送的套管)而处于高感染风险之中。在澳大利亚和新西兰,ECMO 患者(包括 ECMO 套管相关感染)的医院感染发生率尚未得到很好的描述。
这是一项在澳大利亚和新西兰的 11 个 ECMO 中心进行的为期 12 个月的前瞻性、观察性时点患病率研究。在 12 个预定的数据收集周内,将为每位接受 ECMO 的患者收集数据。主要结局是实验室确诊的血流感染和疑似或可能的医院感染的患病率;次要结局包括描述 ECMO 套管的敷料和固定方法以及对当地敷料和固定指南的依从性。数据收集将于 2019 年 3 月完成。
已获得相关伦理和治理批准。研究结果将描述在澳大利亚和新西兰接受 ECMO 的成人、儿科和新生儿患者中疑似和确诊的医院感染的患病率。预计结果将具有启发性,并导致旨在降低这一人群中高感染率的干预性试验。研究结果将发表在同行评议的期刊上,并在相关会议上展示。
ANZCTRN12618001109291;预结果。